TORAX MEDICAL NAMES VETERAN INDUSTRY EXECUTIVE TO LEAD GLOBAL COMMERCIALIZATION EFFORT
September 12, 2012 07:00 AM Eastern Daylight Time
ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical announced today that Eric Masingale has joined the company as Global
Vice President of Sales and Marketing. Eric comes to Torax Medical after 18 years with Stryker Corp (NYSE: SYK), where he
recently held the position of VP of Sales and Global Marketing for the surgical endoscopy division. Over the last 6 years he
played a significant role in growing the division’s sales to nearly $1B.
Eric will lead world-wide commercial expansion of Torax Medical’s unique family of products.
In the US, the LINX® Reflux Management System is available for the treatment of Gastroesophageal
reflux disease (GERD). The LINX System was recently approved by the US Food
and Drug Administration in March 2012 following a unanimous recommendation by a FDA
advisory review panel. The LINX System is currently available in medical centers with
expertise in the diagnosis and minimally invasive treatment of GERD.
Internationally, Eric will also be leading Torax’s European sales organization, based in
London UK, which is focused on emerging markets for the LINX System and the FENIX™
Continence Restoration System, indicated for fecal incontinence (FI). Both products are CE
Torax Medical President and CEO, Todd Berg, commented, “Eric has extensive experience in
building world-class sales teams and driving significant sales growth in minimally invasive
surgery. His established reputation with medical institutions and physician thought leaders
makes him the ideal person to lead our efforts to commercialize the company’s pioneering
products for the treatment of GERD and FI.”
About Torax Medical
Torax Medical, Inc. is a privately held medical device company headquartered in St. Paul, Minnesota that develops and
markets products designed to treat chronic diseases related to defective sphincter muscles. The Company’s technology
platform, Magnetic Sphincter Augmentation (MSA), employs a small implant comprised of interlinked titanium beads with
magnetic cores. The magnetic attraction between the beads augments the existing sphincter’s barrier function to prevent reflux
or incontinence. The devices are implanted with standard minimally invasive laparoscopic or surgical procedures. The LINX
Reflux Management System for the treatment of GERD is marketed in both the USA and in Europe and the FENIX Continence
Restoration System for the treatment of Fecal Incontinence (FI) is marketed in Europe.
Gastroesophageal Reflux Disease (GERD) is a chronic, often progressive disease resulting from a weak lower esophageal
sphincter that allows harmful gastric fluid to reflux into the esophagus. Symptoms of GERD include heartburn, regurgitation,
inability to sleep, and dietary constraints. Acid suppression drugs, such as Prevacid®, Nexium®, and Prilosec®, affect gastric
acid production, but do not repair the sphincter defect and allow continued reflux. GERD can progress to a pre-cancerous
condition known as Barrett’s esophagus and possibly esophageal cancer. Approximately 7% of adults in western countries
suffer daily from symptoms of GERD.
Fecal Incontinence (FI) is the inability to control your bowel movements. The impact of FI on patients’ quality of life can be
debilitating, causing absence from work and limiting the ability to engage in normal daily activities. FI affects an estimated 30
million people in the U.S. and Europe. Studies suggest FI is more prevalent in women and increases with age, but men and
women of all ages can be affected.
Torax Medical investors: Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Ventures, Kaiser Permanente
Ventures and Mayo Medical Ventures. For more information, please visit
Torax Medical, Inc.
Todd Berg, 651-361-8900
President and CEO